Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Macy's Inc (M) vs Medpace Holdings Inc (MEDP) Price & Performance

Macy's IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Macy's Inc vs Medpace Holdings Inc — how do they compare? Macy's Inc trades at $23.39 (market cap $6.13B), while Medpace Holdings Inc trades at $530.58 (market cap $15.08B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Macy's Inc's market cap, and Macy's Inc pays a 3.29% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MMEDP
Market Cap
$6.13B$15.08B
Sector
Consumer CyclicalTechnology
52-Week High
$25.96$620.59
52-Week Low
$11.90$308.88
Enterprise Value
$9.95B$14.55B
Dividend Yield
3.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Macy's Inc

Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.

The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP